Journal
ONCOIMMUNOLOGY
Volume 11, Issue 1, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2022.2096363
Keywords
Dendritic cells; DAMPs; TAAs; antigen cross-presentation; T cell priming; immune checkpoint blockers; tumor-infiltrating lymphocytes; clinical trial
Categories
Funding
- Research Foundation Flanders (FWO) [G0B4620N, T00216N]
- Excellence of Science/EOS grant [30837538]
- KU Leuven [C14/19/098, C3/21/037, POR/16/040]
- Kom op Tegen Kanker (Stand Up To Cancer, the Flemish Cancer Society) [KOTK/2018/11509/1, KOTK/2019/11955/1, KotK_UA/2018/11465/1, KotK_UZA/2018/11465/1]
- VLIR-UoS (iBOF) [iBOF/21/048]
- Kom op tegen Kanker (Stand up to Cancer)
- Flemish Cancer Society [12699, 3328]
- FWO-SB PhD Fellowship [1S06821N]
- KU Leuven's Postdoctoral mandate grant [PDMT1/21/032]
- FWO Senior Clinical Investigator Fellowship [1801520N]
- Health Holland [LSHM18056-SGF]
- Stichting tegen Kanker (Foundation against Cancer) [CA/2016/753, CA/2020/1496]
- Stichting Semmy (Semmy Foundation)
- UZA foundation
- Dutch Brain Tumor Foundation
- Belgian National Cancer Plan
- Olivia Hendrickx Research Fund vzw
Ask authors/readers for more resources
DC-based vaccination for cancer treatment has advanced significantly over recent decades, but still shows suboptimal anti-tumor efficacy in the clinic. Current efforts are focused on improving the immunogenicity and efficacy of DC vaccines in oncology.
Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to recent paradigm-shifts in immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed to tumor-associated or -specific antigens (TAAs or TSAs), in the presence of immunostimulatory molecules to induce DC maturation, followed by reinfusion into patients. Accordingly, DC vaccines can induce TAA/TSA-specific CD8(+)/CD4(+) T cell responses. Yet, DC vaccination still shows suboptimal anti-tumor efficacy in the clinic. Extensive efforts are ongoing to improve the immunogenicity and efficacy of DC vaccines, often by employing combinatorial chemo-immunotherapy regimens. In this Trial Watch, we summarize the recent preclinical and clinical developments in this field and discuss the ongoing trends and future perspectives of DC-based immunotherapy for oncological indications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available